Rohto Pharmaceutical Co Ltd
Rohto Pharmaceutical's GHG Emissions Data Preview
In 2023, Rohto Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Rohto Pharmaceutical has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Rohto Pharmaceutical's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Rohto Pharmaceutical amounted to 12,722 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Rohto Pharmaceutical decreased by 4.52%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
Rohto Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Rohto Pharmaceutical's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Rohto Pharmaceutical were 7,613 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Rohto Pharmaceutical reduced its Scope 1 emissions over time?
Since 2018, Rohto Pharmaceutical's Scope 1 emissions have increased by 58.6%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Rohto Pharmaceutical's Scope 1 emissions increased by 3.05%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
What are Rohto Pharmaceutical's Scope 2 emissions?
In 2023, Rohto Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 5,109 tCOâ‚‚e using the market-based method.
Has Rohto Pharmaceutical reduced its Scope 2 emissions over time?
Compared to the previous year (2022), Rohto Pharmaceutical's Scope 2 emissions (Market-Based) fell by 13.93% in 2023, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.
What methodology does Rohto Pharmaceutical use for Scope 2 reporting?
In 2023, Rohto Pharmaceutical reported its Scope 2 emissions using the market-based method.
Rohto Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 Market-Based
- Total Scope 2 (Unspecified Calculation Method)
Insights into Rohto Pharmaceutical's Value Chain Emissions
In 2023, Rohto Pharmaceutical reported 227,516 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Rohto Pharmaceutical includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year.
Rohto Pharmaceutical's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Rohto Pharmaceutical's Scope 3 emissions?
In 2023, Rohto Pharmaceutical reported total Scope 3 emissions of 227,516 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 98.04% of these emissions originated from upstream activities such as purchased goods and capital goods, while 1.96% came from downstream activities like product use, distribution, and end-of-life treatment.
Compared to the previous year (2022), Rohto Pharmaceutical's Scope 3 emissions increased by 17.51%, suggesting that the company faced challenges in reducing emissions across its value chain.
What categories of Scope 3 emissions does Rohto Pharmaceutical disclose?
In 2023, Rohto Pharmaceutical reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol.
This reflects a high level of granularity and transparency in the company's emissions reporting.
What are the main sources of Rohto Pharmaceutical's Scope 3 emissions?
In 2023, the largest contributors to Rohto Pharmaceutical's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 195,896 tCOâ‚‚e (86.1%)
- Capital Goods (Cat. 2): 13,171 tCOâ‚‚e (5.79%)
- Upstream Transportation and Distribution (Cat. 4): 4,671 tCOâ‚‚e (2.05%)
Rohto Pharmaceutical's Scope 3 Emissions by Categories
Insights into Rohto Pharmaceutical's Total Carbon Footprint
In 2023, Rohto Pharmaceutical reported a total carbon footprint of 240,238 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 16.09% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Rohto Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 94.7% of the company's total carbon footprint, followed by Scope 1 emissions at 3.17%.